AERI Aerie Pharmaceuticals, Inc. Stock Quote

AERI [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | USA

Index	-	P/E	-	EPS (ttm)	-4.19	Insider Own	0.50%	Shs Outstand	45.95M	Perf Week	19.14%
Market Cap	795.95M	Forward P/E	-	EPS next Y	-2.41	Insider Trans	-11.25%	Shs Float	45.83M	Perf Month	28.13%
Income	-192.00M	PEG	-	EPS next Q	-0.73	Inst Own	-	Short Float	12.77%	Perf Quarter	83.72%
Sales	83.10M	P/S	9.58	EPS this Y	21.30%	Inst Trans	0.68%	Short Ratio	9.08	Perf Half Y	33.31%
Book/sh	1.31	P/B	12.83	EPS next Y	19.40%	ROA	-47.50%	Target Price	-	Perf Year	-25.49%
Cash/sh	4.61	P/C	3.64	EPS next 5Y	-	ROE	-173.00%	52W Range	9.01 - 23.04	Perf YTD	24.43%
Dividend	-	P/FCF	-	EPS past 5Y	-17.10%	ROI	-52.70%	52W High	-27.04%	Beta	0.63
Dividend %	-	Quick Ratio	3.10	Sales past 5Y	-	Gross Margin	75.40%	52W Low	86.57%	ATR	0.81
Employees	380	Current Ratio	3.30	Sales Q/Q	8.60%	Oper. Margin	-	RSI (14)	77.32	Volatility	7.59% 5.94%
Optionable	Yes	Debt/Eq	3.41	EPS Q/Q	20.60%	Profit Margin	-	Rel Volume	1.36	Prev Close	16.50
Shortable	Yes	LT Debt/Eq	3.41	Earnings	Nov 05 AMC	Payout	-	Avg Volume	644.60K	Price	16.81
Recom	1.90	SMA20	18.67%	SMA50	26.55%	SMA200	28.33%	Volume	878,378	Change	1.88%

Oct-19-20

Downgrade

BofA Securities

Neutral → Underperform

$14 → $9

Sep-08-20

Resumed

Guggenheim

Buy

$20

Aug-07-20

Reiterated

Needham

Buy

$32 → $26

Jun-01-20

Resumed

Oppenheimer

Outperform

$22 → $24

May-07-20

Reiterated

H.C. Wainwright

Buy

$37 → $31

Jan-10-20

Initiated

BofA/Merrill

Neutral

$27

Jan-09-20

Initiated

SunTrust

Buy

$32

Dec-19-19

Initiated

Citigroup

Buy

$36

Nov-07-19

Reiterated

H.C. Wainwright

Buy

$55 → $41

Oct-30-19

Reiterated

Needham

Buy

$54 → $48

Aug-08-19

Reiterated

Needham

Buy

$74 → $54

Aug-08-19

Reiterated

Cantor Fitzgerald

Overweight

$85 → $62

Mar-21-19

Initiated

Piper Jaffray

Overweight

$80

Jul-13-18

Reiterated

Needham

Buy

$76 → $86

Feb-16-18

Resumed

H.C. Wainwright

Buy

$78

Jan-26-18

Initiated

Seaport Global Securities

Buy

$78

Oct-24-17

Initiated

Guggenheim

Buy

$80

Oct-16-17

Reiterated

Needham

Buy

$65 → $76

Jul-20-17

Reiterated

Cantor Fitzgerald

Overweight

$56 → $62

May-25-17

Reiterated

Needham

Buy

$58 → $65

Jan-11-21 06:30AM	Aerie Pharmaceuticals Receives European Commission Approval for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Business Wire
Dec-16-20 11:07PM	Is AERI A Good Stock To Buy Now? Insider Monkey
Dec-05-20 11:31AM	Why Is Aerie (AERI) Up 19% Since Last Earnings Report? Zacks
Dec-03-20 11:17PM	What Did Aerie Pharmaceuticals' (NASDAQ:AERI) CEO Take Home Last Year? Simply Wall St.
Nov-25-20 10:36AM	Bausch (BHC) Begins Second Phase III Study on NOV03 for DED Zacks
Nov-16-20 10:06AM	Aerie (AERI) Gets Positive CHMP Opinion for Roclanda in EU Zacks
Nov-13-20 06:50AM	Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda® in the European Union Business Wire
Nov-10-20 07:30AM	Aerie Pharmaceuticals to Participate in the Stifel 2020 Virtual Healthcare Conference Business Wire
Nov-07-20 01:30AM	Aerie Pharmaceuticals Inc (AERI) Q3 2020 Earnings Call Transcript Motley Fool
Nov-06-20 10:50AM	Aerie (AERI) Q3 Loss Narrower Than Expected, Sales Rise Y/Y Zacks
Nov-05-20 06:25PM	Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM	Aerie Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update Business Wire
03:45PM	Aerie Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Nov-03-20 09:46AM	3 Strong Buy Stocks Poised for a Year-End Rally TipRanks
Oct-29-20 12:35PM	Aerie Pharmaceuticals (AERI) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Zacks
06:30AM	Aerie Pharmaceuticals Initiates Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease Business Wire
Oct-28-20 03:00AM	Santen and Aerie Conclude Exclusive License Agreement for Rhopressa® and Rocklatan® in Japan and Several Other Asian Countries Business Wire
Oct-27-20 07:30AM	Aerie Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host Conference Call on Thursday, November 5, 2020 Business Wire
Oct-20-20 06:28AM	Aerie Pharmaceuticals' (NASDAQ:AERI) Stock Price Has Reduced 85% In The Past Three Years Simply Wall St. -8.06%
Oct-15-20 09:20AM	New Strong Sell Stocks for October 15th Zacks
Oct-14-20 12:30AM	Aerie E-commerce Demand Surges 113 Percent in Pandemic WWD
Oct-05-20 12:01PM	Here is What Hedge Funds Think About Aerie Pharmaceuticals Inc (AERI) Insider Monkey
Sep-30-20 09:10AM	Aerie to Initiate Phase IIb Study for Dry Eye Treatment Zacks
Sep-29-20 06:30AM	Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-15512 (TRPM8 Agonist) Eye Drop for Dry Eye Disease Business Wire
Sep-24-20 06:30AM	Aerie Pharmaceuticals Announces Successful Interim 90-Day Topline Data From Its Six-Month Mercury 3 Clinical Trial in Europe Business Wire
Sep-18-20 09:00AM	Can American Eagle Outfitters Succeed in Athleisure? Motley Fool
Sep-15-20 06:45AM	Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rhopressa® (netarsudil ophthalmic solution) 0.02% Business Wire
Sep-09-20 07:45AM	American Eagle Outfitters Promotes Jennifer Foyle to Chief Creative Officer WWD
Sep-08-20 07:30AM	Aerie Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences Business Wire
Sep-05-20 11:31AM	Why Is Aerie (AERI) Down 3.6% Since Last Earnings Report? Zacks
Aug-21-20 09:01AM	Aerie Pharmaceuticals, Inc. (NASDAQ:AERI): When Will It Breakeven? Simply Wall St. -6.48%
Aug-10-20 10:01AM	New Strong Sell Stocks for August 10th Zacks
Aug-07-20 10:53AM	Aerie (AERI) Q2 Earnings Miss Estimates, Revenues Rise Y/Y Zacks
Aug-06-20 04:01PM	Aerie Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update Business Wire
Jul-30-20 07:30AM	Aerie Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host Conference Call on Thursday, August 6, 2020 Business Wire
Jul-29-20 12:33PM	Will Aerie Pharmaceuticals (AERI) Report Negative Q2 Earnings? What You Should Know Zacks
Jul-27-20 06:30AM	Aerie Pharmaceuticals Reports Positive Topline Results for AR-1105 (Dexamethasone Intravitreal Implant) Phase 2 Clinical Trial in Patients with Macular Edema Due to Retinal Vein Occlusion Business Wire
Jul-17-20 02:06PM	Did Hedge Funds Make The Right Call On Aerie Pharmaceuticals Inc (AERI) ? Insider Monkey
Jul-02-20 08:11AM	Is Aerie Pharmaceuticals a Buy? Motley Fool
Jun-15-20 06:04PM	Aerie Pharmaceuticals Inc (AERI): Hedge Funds Are Nibbling Insider Monkey
Jun-11-20 06:30AM	Aerie Pharmaceuticals Appoints Peter J. McDonnell, M.D., to the Companys Board of Directors Business Wire -11.30%
Jun-05-20 11:31AM	Aerie (AERI) Up 1.9% Since Last Earnings Report: Can It Continue? Zacks
Jun-03-20 03:40AM	Edited Transcript of AERI earnings conference call or presentation 6-May-20 9:00pm GMT Thomson Reuters StreetEvents
May-11-20 07:15PM	Was The Smart Money Right About Aerie Pharmaceuticals Inc (AERI)? Insider Monkey +5.04%
May-07-20 06:30PM	Aerie Pharmaceuticals Inc (AERI) Q1 2020 Earnings Call Transcript Motley Fool -7.79%
May-06-20 05:15PM	Aerie Pharmaceuticals (AERI) Reports Q1 Loss, Lags Revenue Estimates Zacks
04:01PM	Aerie Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update Business Wire
03:00PM	Aerie Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
May-05-20 07:30AM	Aerie Pharmaceuticals to Present at the Bank of America Securities 2020 Healthcare Conference Business Wire
Apr-29-20 07:30AM	Aerie Pharmaceuticals to Announce First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020 Business Wire +9.81%
Apr-28-20 12:34PM	Aerie Pharmaceuticals (AERI) Expected to Beat Earnings Estimates: Should You Buy? Zacks -5.22%
Apr-13-20 10:01AM	Aerie (AERI) Suspends Guidance Due to Coronavirus Outbreak Zacks
Apr-09-20 04:01PM	Aerie Pharmaceuticals Provides 2020 Company and Guidance Update Associated with COVID-19 Business Wire +13.81%
Apr-07-20 07:30AM	Aerie Pharmaceuticals to Present at the Needham Virtual Healthcare Conference Business Wire +5.92%
Apr-02-20 02:54PM	Gone: Triangle public companies lose $30 billion in value during 1Q 2020 American City Business Journals
Mar-25-20 10:18AM	Healthcare Pro James Flynn Picks up These 3 Stocks on the Cheap TipRanks
Mar-21-20 11:30AM	Why Is Aerie (AERI) Down 40.5% Since Last Earnings Report? Zacks
Feb-27-20 07:23AM	Edited Transcript of AERI earnings conference call or presentation 20-Feb-20 10:00pm GMT Thomson Reuters StreetEvents -9.18%
05:19AM	Aerie Pharmaceuticals, Inc. Just Released Its Yearly Results And Analysts Are Updating Their Estimates Simply Wall St.
Feb-24-20 02:59PM	Advance Auto Parts, Cree among Triangle companies hit as stocks tumble with rising concern over coronavirus American City Business Journals -5.97%
07:30AM	Aerie Pharmaceuticals to Present at the Cowen 40th Annual Healthcare Conference Business Wire
Feb-21-20 11:30AM	Aerie's (AERI) Q4 Loss Wider Than Expected, Revenues Beat Zacks +8.55%
07:46AM	The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion Benzinga
Feb-20-20 05:35PM	Aerie Pharmaceuticals (AERI) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:01PM	Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results, Provides 2020 Guidance and Business Update Business Wire
10:50AM	Some Market Stats In 5 Minutes Benzinga
Feb-18-20 06:30AM	Aerie Pharmaceuticals Announces Appointment of Nina Ohara, PharmD, M.B.A, as Director, Marketing and Gregory Jones, CPA, as Director, Tax Business Wire
Feb-13-20 07:30AM	Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Thursday, February 20, 2020 Business Wire
Feb-12-20 05:13AM	Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI) Path To Profitability Simply Wall St.
Feb-03-20 06:30AM	Aerie Pharmaceuticals Announces Appointment of Michelle Senchyna, Ph.D., as Vice President, Clinical Development and Medical Affairs Business Wire
Jan-21-20 06:30AM	Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Business Wire
Jan-08-20 05:18PM	How Did Aerie Pharmaceuticals Inc (AERI) Perform In Comparison to Hedge Fund Favorites in 2019? Insider Monkey
Jan-07-20 05:26AM	Does Aerie Pharmaceuticals (NASDAQ:AERI) Have A Healthy Balance Sheet? Simply Wall St.
Jan-03-20 10:04AM	Aerie's (AERI) Application for Roclanda Accepted in Europe Zacks
Jan-02-20 08:46AM	The Daily Biotech Pulse: Canadian Approval For Amarin's Vascepa, Innate Pharma's Blood Cancer Drug Accepted For Review In Europe Benzinga
06:30AM	Aerie Pharmaceuticals Announces Acceptance for Review of the Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Marketing Authorisation Application in Europe Business Wire
Dec-09-19 06:30AM	Aerie Pharmaceuticals Announces Appointment of Amine Sinmazisik as Director, Finance Business Wire +5.91%
Dec-06-19 11:31AM	Aerie (AERI) Up 4.7% Since Last Earnings Report: Can It Continue? Zacks
Dec-04-19 09:19AM	Is Aerie Pharmaceuticals Inc (AERI) A Good Stock To Buy ? Insider Monkey +6.32%
Dec-03-19 06:15AM	Aerie Pharmaceuticals Submits Marketing Authorisation Application for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% in Europe Business Wire
Dec-02-19 04:56AM	Did Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Insiders Buy Up More Shares? Simply Wall St.
Nov-27-19 09:45AM	5 Strong Buy Biotech Stocks With More Than 80% Upside InvestorPlace
Nov-26-19 06:30AM	Aerie Pharmaceuticals to Present at the Piper Jaffray 31st Annual Healthcare Conference TEST Business Wire Releases
06:30AM	Aerie Pharmaceuticals to Present at the Piper Jaffray 31st Annual Healthcare Conference Business Wire
Nov-22-19 08:18AM	The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate Benzinga
Nov-21-19 06:30AM	Aerie Pharmaceuticals Receives European Commission Approval for Rhokiinsa® (netarsudil ophthalmic solution) 0.02% Business Wire
Nov-19-19 10:58AM	Aerie buys Spanish outfit as it moves toward profitability American City Business Journals
09:31AM	Aerie to Acquire Dry Eye Disease-Focused Pharma Avizorex Zacks
Nov-18-19 06:30AM	Aerie Pharmaceuticals Announces Agreement to Acquire Avizorex Pharma, S.L. to Advance Its Dry Eye Program Business Wire
Nov-12-19 07:30AM	Aerie Pharmaceuticals to Present at the Stifel 2019 Healthcare Conference Business Wire
05:41AM	Edited Transcript of AERI earnings conference call or presentation 6-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-07-19 10:51AM	Aerie (AERI) Q3 Loss Wider, Sales Beat, Guidance Slashed Zacks -22.42%
07:18AM	The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs Benzinga
Nov-06-19 06:05PM	Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM	Aerie Pharmaceuticals Reports Third Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance and Provides Business Update Business Wire
Nov-05-19 06:30AM	Aerie Pharmaceuticals Announces Positive Topline Results for Netarsudil Ophthalmic Solution in Phase 2 Study Conducted in Japan Business Wire
Oct-30-19 07:30AM	Aerie Pharmaceuticals to Announce Third Quarter 2019 Financial Results and Host Conference Call on Wednesday, November 6, 2019 Business Wire
06:30AM	Aerie Pharmaceuticals Announces the Appointment of David A. Hollander, M.D., M.B.A., as Chief Research & Development Officer Business Wire
Oct-29-19 10:33AM	Aerie Pharmaceuticals (AERI) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Zacks
Oct-28-19 06:13PM	Is Aerie Pharmaceuticals Inc (AERI) Going To Burn These Hedge Funds ? Insider Monkey +5.44%

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, dry eye, retinal diseases, and other eye diseases. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. The company is also developing AVX-012, a clinical-stage dry eye product candidate; and AR-1105 and AR-13503 sustained-release implants for treating retinal diseases. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kopczynski Casey C.	Chief Scientific Officer	Nov 11	Sale	13.01	22,695	295,210	196,114	Nov 12 05:03 PM
Kopczynski Casey C.	Chief Scientific Officer	Nov 10	Sale	13.00	7,305	94,965	218,809	Nov 12 05:03 PM
GOLDBERG MURRAY A	Director	May 18	Option Exercise	3.15	28,000	88,200	36,050	May 20 06:45 PM
Cagle Gerald D.	Director	May 08	Sale	15.27	5,000	76,350	16,550	May 12 05:25 PM
Foresite Capital Management II	10% Owner	Feb 27	Sale	17.07	1,000,000	17,070,000	1,229,633	Mar 02 05:01 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience